Johnson & Johnson stock enters TCT week with 26 Impella presentations

Published on 11/01/2026 at 17:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock faces a key MedTech presentation on Monday in San Diego. The program will spotlight Impella evidence and heart-recovery products.

MedTech focus moves into TCT week

Johnson & Johnson will present new Impella evidence at the TCT 2026 meeting in San Diego.
A Monday symposium will focus on heart recovery, clinical evidence and future device development.
The MedTech agenda gives investors a near-term readout on the company's cardiovascular technology pipeline.

Johnson & Johnson, US4781601046, Illustration mit AI erstellt.

Johnson & Johnson will bring 26 Impella presentations to the TCT 2026 meeting in San Diego, with the next scheduled company program on Monday, November 2. The company announced the agenda in a Johnson & Johnson press release published on October 29.

Impella evidence takes center stage

The company's program covers heart recovery and high-risk percutaneous coronary intervention. The agenda includes clinical analyses on mortality, patient selection and the use of microaxial-flow pumps in complex procedures.

Johnson & Johnson will also host the symposium Leading in Heart Recovery: Lessons Learned from the Clinical and Scientific Experience with Impella on Monday from 7:45 to 8:45 a.m. Pacific time at the World Connect Theater in San Diego. The company's HeartRecovery event page lists the session and the broader booth program running through November 3.

What the program means for investors

The TCT schedule gives investors a near-term view of the evidence supporting Johnson & Johnson's MedTech portfolio. The presentations may help frame how the company positions Impella in heart-recovery care, but conference data do not by themselves change revenue or earnings expectations.

The real-time quote of Johnson & Johnson stock was 245.80 euros on Lang & Schwarz at 17:27 CET on Sunday, November 1, 2026.